Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus

Jaehyun Bae, Youjin Kim, Yongin Cho, Minyoung Lee, Ji Yeon Lee, Yong ho Lee, Byung Wan Lee, Bong Soo Cha, Dong Jin Joo, Kyu Ha Huh, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang

Research output: Contribution to journalArticle

Abstract

Background: Gemigliptin is a potent, selective dipeptidyl peptidase (DPP)-4 inhibitor that does not require any dosage adjustment based on renal function. It is also known to have no apparent interaction with commonly used drugs. In the present study, we aimed to evaluate the glucose-lowering efficacy and safety of gemigliptin in post-transplant patients with type 2 diabetes mellitus (T2D). Methods: A total of 84 patients who were prescribed gemigliptin for more than 180 days after transplantation were analyzed retrospectively. Six-month changes in blood glucose and glycated hemoglobin (HbA1c) levels were checked to assess glycemic efficacy. Safety was evaluated by examining its influence on immunosuppressive treatment, as determined by the blood trough level and dosage of calcineurin inhibitors, as well as changes in parameters related to liver and renal function. Results: Six months of gemigliptin treatment significantly lowered blood glucose level (HbA1c: 8.16 ± 1.69 to 7.44 ± 1.26%; P <.001). There were no significant changes in blood trough levels of immunosuppressants, including tacrolimus, cyclosporine, and sirolimus. The dosage of immunosuppressants was also stable. In addition, there were no significant changes in the levels of liver enzymes and renal function during 6 months of treatment. Conclusion: Gemigliptin robustly lowered blood glucose levels without exerting any significant effect on immunosuppressive treatment, renal function, and liver enzymes in post-transplant patients with T2D.

Original languageEnglish
Pages (from-to)3444-3448
Number of pages5
JournalTransplantation Proceedings
Volume51
Issue number10
DOIs
Publication statusPublished - 2019 Dec

Fingerprint

Type 2 Diabetes Mellitus
Immunosuppressive Agents
Transplants
Safety
Kidney
Blood Glucose
Liver
Dipeptidyl-Peptidase IV Inhibitors
Glycosylated Hemoglobin A
Tacrolimus
Sirolimus
Enzymes
Therapeutics
Cyclosporine
Transplantation
LC15-0444
Glucose
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Bae, Jaehyun ; Kim, Youjin ; Cho, Yongin ; Lee, Minyoung ; Lee, Ji Yeon ; Lee, Yong ho ; Lee, Byung Wan ; Cha, Bong Soo ; Joo, Dong Jin ; Huh, Kyu Ha ; Kim, Myoung Soo ; Kim, Yu Seun ; Kang, Eun Seok. / Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus. In: Transplantation Proceedings. 2019 ; Vol. 51, No. 10. pp. 3444-3448.
@article{3b0970958e074cd4b28591628848eea8,
title = "Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus",
abstract = "Background: Gemigliptin is a potent, selective dipeptidyl peptidase (DPP)-4 inhibitor that does not require any dosage adjustment based on renal function. It is also known to have no apparent interaction with commonly used drugs. In the present study, we aimed to evaluate the glucose-lowering efficacy and safety of gemigliptin in post-transplant patients with type 2 diabetes mellitus (T2D). Methods: A total of 84 patients who were prescribed gemigliptin for more than 180 days after transplantation were analyzed retrospectively. Six-month changes in blood glucose and glycated hemoglobin (HbA1c) levels were checked to assess glycemic efficacy. Safety was evaluated by examining its influence on immunosuppressive treatment, as determined by the blood trough level and dosage of calcineurin inhibitors, as well as changes in parameters related to liver and renal function. Results: Six months of gemigliptin treatment significantly lowered blood glucose level (HbA1c: 8.16 ± 1.69 to 7.44 ± 1.26{\%}; P <.001). There were no significant changes in blood trough levels of immunosuppressants, including tacrolimus, cyclosporine, and sirolimus. The dosage of immunosuppressants was also stable. In addition, there were no significant changes in the levels of liver enzymes and renal function during 6 months of treatment. Conclusion: Gemigliptin robustly lowered blood glucose levels without exerting any significant effect on immunosuppressive treatment, renal function, and liver enzymes in post-transplant patients with T2D.",
author = "Jaehyun Bae and Youjin Kim and Yongin Cho and Minyoung Lee and Lee, {Ji Yeon} and Lee, {Yong ho} and Lee, {Byung Wan} and Cha, {Bong Soo} and Joo, {Dong Jin} and Huh, {Kyu Ha} and Kim, {Myoung Soo} and Kim, {Yu Seun} and Kang, {Eun Seok}",
year = "2019",
month = "12",
doi = "10.1016/j.transproceed.2019.07.015",
language = "English",
volume = "51",
pages = "3444--3448",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

Bae, J, Kim, Y, Cho, Y, Lee, M, Lee, JY, Lee, YH, Lee, BW, Cha, BS, Joo, DJ, Huh, KH, Kim, MS, Kim, YS & Kang, ES 2019, 'Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus', Transplantation Proceedings, vol. 51, no. 10, pp. 3444-3448. https://doi.org/10.1016/j.transproceed.2019.07.015

Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus. / Bae, Jaehyun; Kim, Youjin; Cho, Yongin; Lee, Minyoung; Lee, Ji Yeon; Lee, Yong ho; Lee, Byung Wan; Cha, Bong Soo; Joo, Dong Jin; Huh, Kyu Ha; Kim, Myoung Soo; Kim, Yu Seun; Kang, Eun Seok.

In: Transplantation Proceedings, Vol. 51, No. 10, 12.2019, p. 3444-3448.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus

AU - Bae, Jaehyun

AU - Kim, Youjin

AU - Cho, Yongin

AU - Lee, Minyoung

AU - Lee, Ji Yeon

AU - Lee, Yong ho

AU - Lee, Byung Wan

AU - Cha, Bong Soo

AU - Joo, Dong Jin

AU - Huh, Kyu Ha

AU - Kim, Myoung Soo

AU - Kim, Yu Seun

AU - Kang, Eun Seok

PY - 2019/12

Y1 - 2019/12

N2 - Background: Gemigliptin is a potent, selective dipeptidyl peptidase (DPP)-4 inhibitor that does not require any dosage adjustment based on renal function. It is also known to have no apparent interaction with commonly used drugs. In the present study, we aimed to evaluate the glucose-lowering efficacy and safety of gemigliptin in post-transplant patients with type 2 diabetes mellitus (T2D). Methods: A total of 84 patients who were prescribed gemigliptin for more than 180 days after transplantation were analyzed retrospectively. Six-month changes in blood glucose and glycated hemoglobin (HbA1c) levels were checked to assess glycemic efficacy. Safety was evaluated by examining its influence on immunosuppressive treatment, as determined by the blood trough level and dosage of calcineurin inhibitors, as well as changes in parameters related to liver and renal function. Results: Six months of gemigliptin treatment significantly lowered blood glucose level (HbA1c: 8.16 ± 1.69 to 7.44 ± 1.26%; P <.001). There were no significant changes in blood trough levels of immunosuppressants, including tacrolimus, cyclosporine, and sirolimus. The dosage of immunosuppressants was also stable. In addition, there were no significant changes in the levels of liver enzymes and renal function during 6 months of treatment. Conclusion: Gemigliptin robustly lowered blood glucose levels without exerting any significant effect on immunosuppressive treatment, renal function, and liver enzymes in post-transplant patients with T2D.

AB - Background: Gemigliptin is a potent, selective dipeptidyl peptidase (DPP)-4 inhibitor that does not require any dosage adjustment based on renal function. It is also known to have no apparent interaction with commonly used drugs. In the present study, we aimed to evaluate the glucose-lowering efficacy and safety of gemigliptin in post-transplant patients with type 2 diabetes mellitus (T2D). Methods: A total of 84 patients who were prescribed gemigliptin for more than 180 days after transplantation were analyzed retrospectively. Six-month changes in blood glucose and glycated hemoglobin (HbA1c) levels were checked to assess glycemic efficacy. Safety was evaluated by examining its influence on immunosuppressive treatment, as determined by the blood trough level and dosage of calcineurin inhibitors, as well as changes in parameters related to liver and renal function. Results: Six months of gemigliptin treatment significantly lowered blood glucose level (HbA1c: 8.16 ± 1.69 to 7.44 ± 1.26%; P <.001). There were no significant changes in blood trough levels of immunosuppressants, including tacrolimus, cyclosporine, and sirolimus. The dosage of immunosuppressants was also stable. In addition, there were no significant changes in the levels of liver enzymes and renal function during 6 months of treatment. Conclusion: Gemigliptin robustly lowered blood glucose levels without exerting any significant effect on immunosuppressive treatment, renal function, and liver enzymes in post-transplant patients with T2D.

UR - http://www.scopus.com/inward/record.url?scp=85075337311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075337311&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2019.07.015

DO - 10.1016/j.transproceed.2019.07.015

M3 - Article

C2 - 31733799

AN - SCOPUS:85075337311

VL - 51

SP - 3444

EP - 3448

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -